Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex extension study in MS spasticity
NCT01610687Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2001
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cannabis extract in spasticity and multiple sclerosis (MS), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Incidence of Adverse Events as a Measure of Patient Safety up to 1206 days. Started Jul 2001; status: completed.
02
Drugs
cannabis extract
03
Conditions
spasticitymultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01610687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610687.